https://doi.org/10.33805/2639.6807.118
Volume 3 Issue 1 | PDF 118 | Pages 5
Clinical Cardiology and
Cardiovascular Medicine
Research Article
ISSN: 2639-6807
Prevalence of Hyperuricemia and its Association with Other
Cardiovascular Risk Factors in Adult Yemeni People of
Sana’a City
Mohammed Ahmed Bamashmos* and Khaled Al-Aghbari
Affiliation: Internal medicine and Endocrinology, Sana'a University, Yemen
*Corresponding author: Mohammed Ahmed Bamashmos, Associate Professor of internal medicine and Endocrinology, Sana'a
University, Yemen, E-mail: mohbamashmoos@yahoo.com
Citation: Bamashmos AM and Al-Aghbari K. Prevalence of hyperuricemia and its association with other cardiovascular risk factors in adult
Yemeni people of Sana’a city (2019) Clinical Cardiol Cardiovascular Med 3: 10-14.
Received: Jun 14, 2019
Accepted: Jul 04, 2019
Published: Jul 11, 2019
Copyright:© 2019 Bamashmos AM, et al, This is an open-access article distributed under the terms of the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Objective: Hyperuricemia is a metabolic problem that has become increasingly common worldwide over the past several decades. Its prevalence
is increased in both advanced and developing countries including Yemen. The aim of this cross sectional study was to investigate the prevalence
of hyperuricemia in sample of Yemeni adult individual and its relationship to certain cardiovascular risk factors namely obesity, hypertension,
serum glucose, total cholesterol, high serum triglyceride, Low High Density Lipoprotein (HDL-C) and high Low Density Lipoprotein (LDL-C).
Methodology: A sample of 600 adult Yemeni people aged equal or over 18 years was randomly chosen to represent the population living in
Sana’a City during a period of 16 months from April 2017 to August 2018. All the study groups undergo full clinical history and examination
includes measurement of BP and BMI, WC and the following laboratory investigation (FBS, Basal serum uric acid level, total cholesterol, serum
TG, HDL and LDL).
Results: The prevalence of hyperuricemia in this study was 8.8% (11.6% male and 6.4% female). The serum uric acid level in this study was
significantly correlated with age, Waist Circumference (WC), SBP, DBP, FBS, T-cholesterol, TG and LDL but not with HDL.
Conclusion: There is strong relationship between serum uric acid level and other cardiovascular risk factors.
Keywords: Hyperurecemia, Dyslipidemia, BMI, FBS.
Abbreviations: HDL- High Density Lipoprotein, LDL- Low Density Lipoprotein, WC- Waist Circumference, GBD- Global Burden of Diseases, CDCCardiovascular Disease, BMI- Body Mass Index, SUA- Serum Uric Acid, FBS- Fasting Blood Sugar, IFG- Impaired Fasting Glucose, T.Ch- Total
Cholesterol, SPSS- Social Package of Statistical Science, NO- Nitric Oxide.
Introduction
Hyperurecemia is metabolic problem that has become increasingly
worldwide over the past several decades and it’s the most risk factor
for gout [1]. Hyperurecimea is defining as serum urate level greater
than 6mg/dl in in women and 7mg/dl in men, above this concentration
serum urate supersaturates in body fluid and is prone to crystallization
and subsequent deposition in the tissue [2].The association of
hyperurecemia and gout with other medical condition such as
hypertension, chronic kidney diseases, dyslipidemia and other
cardiovascular diseases has been recognized for over 100 years [3].
The prevalence of hyperurecemia has been increased in recent years,
not only in advanced countries but also in developing countries along
with the development with their economics [4]. Published populationbased prevalence data of hyperuricemia were reported in 13 of the 21
Global Burden of Diseases (GBD) regions, and a total of 24 countries.
In most part of Asia Hyperuricemia is relatively prevalent, but in East
Asia it found to be most prevalent. Lowest percentage is seen in Papua
New Guinea 1% and in Marshall Islands 85% is seen.
In japan the high income Asian country Hyperuricemia has increased
by five folds in time of two decades. There is no published populationbased epidemiological studies on hyperuricemia were identified during
the specified systematic review period [5]. Hyperuricemia can be
causes by over production of urate which account of less than 10% of
the cause such as high cellular turnover, genetic error and tumor lysis
syndrome or far more commonly inefficient excretion by the kidney
due to renal insufficiency of any cause or medication that impair renal
urate clearance [6]. In numerous epidemiological studies since 1950 a
positive association has been seen between serum uric acid and
cardiovascular diseases such as ischemic heart disease and stroke [7,8].
However weather uric acid is independent risk factor for cardiovascular
disease is still disputed as several studies has suggested that
hyperurecemia is merely associated with cardiovascular disease
because of confounding factors such as obesity, hypertension,
dyslipidemia, use of diuretic and insulin resistance [9]. Obesity and
central fat distribution were associated with hyperurecemia. Patients
with central obesity have greater risk of hyperurecemia [4].
Citation: Bamashmos AM and Al-Aghbari K. Prevalence of hyperuricemia and its association with
other cardiovascular risk factors in adult Yemeni people of Sana’a city (2019) Clinical Cardiol
Cardiovascular Med 3: 10-14.
10
Bamashmos AM, et al. Clinical Cardiology and Cardiovascular, 2019 PDF: 118, 3:1
There are many researches was conducted to evaluate the relationship
between leptin hormone and the cluster of hyperurecemia in order to
identify the pathogenic mechanism associating obesity with
hyperurecemia. It was suggested that leptin could be a pathogenic
factor responsible for hyperurecemia in obese patients [10]. The strong
association between hypertension and hyperurecemia has been
recognized for more than century. More than one large epidemiological
studies published over the past 7 years have found that serum urate
level predict later development of hypertension [11,12].
Experimental studies have reported that hyperurecemia induces
systemic hypertension and renal injury via activation of renin
angiotensin system and direct intery of uric acid into both endothelial
and vascular smooth muscle cells, decreased neuronal nitric oxide
synthase in the juxtaglomerular apparatus resulting in local inhibition
of endothelial nitric oxide level, stimulation of vascular smooth muscle
cell proliferation and stimulation of vasoactive and inflammatory
mediators [13,14]. There is strong association between
hypertriglycemia and hyperurecemia this association could be
explained by insulin resistance as hypertriglyceridemia and
hyperurecemia are suggested to be associated with insulin resistance
syndrome [15].
The association of hypertriglyceridemia and hyperurecemia in patients
with insulin resistance syndrome could be explained by accumulation
of glycolytic intermediate and release of free fatty acid from adipose
tissue [16]. The resemblance of hyperurecemia and the metabolic
syndrome has led to the suggestion that the metabolic syndrome can be
further expanded to include hyperurecemia [17]. A prospective study in
Korea suggested that higher uric acid concentration predicted the
incidence of hypertension and the development of metabolic syndrome
and hyperurecemia has been considered as component of metabolic
syndrome [18,19].
Material and method
This was across sectional population based study conducted in Sana’a
city for a period of 16 months from April 2017 to August 2018, a
sample of 600 adult Yemeni people (275 male and 325 female aged ≥
18 years) was randomly selected from those attending Al-Kuwait
University Hospital and Consultation Clinic. All the participants in this
study undergo complete clinical history (regarding their age,
occupation, habit, any history of hypertension, diabetes mellitus,
dyslipidemia and medication) Anthropometric measurement includes
measurement of height, weight, waist circumference and systolic and
diastolic blood pressure.
Height was measured with tapeline to the nearest.5cm and weight was
measured with beam scale balance. Participants wore light clothing and
were asked to remove shoes, heavy outer garments Body Mass Index
(BMI: kg/m2) was calculated from measured weight and height. BMI
was classified as underweight (<18.5 kg/m2), normal (18.5-25 kg/m2),
overweight (25-30 kg/m2) and obese (>30 kg/m2) by WHO criteria
[20]. Waist circumference was manually measured on standing subjects
with soft tape midway between the lowest rib and the iliac crest.
Abdominal obesity was defined as WC ≥ 90 cm (male) or WC ≥ 80 cm
(female) by IDF consensus [21].
Two blood pressure recording were obtained from the right arm of
patients with slandered mercury sphygmomanometer in a sitting
position after 10 min. of rest measurement were taken in 3-5 minutes
interval and the mean values were calculated. Blood pressure was
classified as normotensive (SBP<120 mmHg and DBP<80 mmHg),
pre-hypertensive (SBP: 120-139 mmHg and/or DBP: 80-89 mmHg)
and hypertensive (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) by the
Seventh Report of the Joint National Committee on the Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7)
[22]. The American Diabetes Association criteria was used to classify
FBG as normal glucose (FBG<5.6 mmol/L), Impaired Fasting Glucose
(IFG) (FBG ≥ 5.6 mmol/L ≤ FBG<7.0 mmol/L), and diabetic (FBG ≥
7.0 mmol/L, Serum uric acid were measured [23]. Hyperurecemia is
defined as serum uric acid level greater than 6.0mg/|dl in women and
7.0 mg/dl in men. Dyslipidemia was classified according to ATP III,
TG: Normal<1.69 mmol/L, Borderline high 1.69-2.26 mmol/L, High
2.26-5.65 mmol/L, Very high ≥ 5.65 mmol/L; TC: Desirable<5.17
mmol/L, Borderline high 5.17-6.24 mmol/L, High ≥ 6.24 mmol/L;
HDL-C: High 1.56 mmol/L, Optimal 1.03-1.56 mmol/L, Low<l.03
mmol/L; LDL-C: Optimal<2.59 mmol/L, Near optimal 2.59-3.38
mmol/L, Borderline high 3.38-4.16 mmol/L, High 4.16-4.94 mmol/L,
Very high ≥ 4.94 mmol/L [24].
The results were analyzed by using (Social Package of Statistical
Science) SPSS V.15 from LEAD Technologies Inc., USA. Basic
characteristics of subjects are presented as mean and slandered
deviation for quantities variables and as frequency and percent for
qualitative variable. The total participants were divided into two groups
according to the sex then there were divided into two mean groups
according to serum uric acid level.
The prevalence of cardiovascular diseases risk factors among two
groups were calculated and Chi-square test was used to detect the
significance /The mean of uric acid in different categories of separated
variable were determined and the comparison between the mean was
achieved by independent t-test and one way ANOVA test. The
relationships between parameters were examined by calculating
person’s correlation coefficient. For investigating for most effective
factors on hyperurecemia such as blood pressure anthropometrical and
biochemical (except UC) measurement were considered for Binary
logistic regression P-value less than 0.05 was considered statistically
significant.
Results
A study sample includes 600 person aged between 18-83 of them 275
(45.4%) were male and 325 (54.6%) were female. The prevalence of
high serum uric acid level in the study group was 53 (8.8%) with no
significant difference between male and female (Table 1) regarding the
clinical and laboratory parameters in the study group BMI. WS, serum
cholesterol, high TG, low high density lipoprotein, high LDL and high
FBS were significantly higher in women than in men (17.2%, 35%,
43.3%, 41.2%, 19.3%, 53.8% and 26.4% vs 13.8%, 14.5%, 27.6%.
27.2%, 8.7%, 38.1% and 19.2% respectively, while the BP was
significantly higher in men than women, also there was no significant
difference between male and female regarding serum uric acid level.
Discussion
Hyperurecemia is increasingly common medical problem not only in
the advanced countries, but also in the developing countries. The
incidence of high serum uric acid is increased word wide with average
of 20% of population having hyperurecemia and the serum uric acid
level is increased with age. It has been described that hyperurecemia is
associated with other cardiovascular risk factors such as obesity,
dyslipidemia, hyperglycemia and hypertension [1-3]. Elevated serum
uric acid levels are commonly seen in association with glucose
intolerance, hypertension and dyslipidemia, a cluster of metabolic and
hemodynamic disorders which characterize the so-called metabolic
syndrome [25-29]. To our knowledge there is no data about the
prevalence of hyperurecemia in Yemen so we decided to carry out this
research in order to know the prevalence of hyperurecemia and its
association with other cardiovascular risk factors in Yemeni
population.
Citation: Bamashmos AM and Al-Aghbari K. Prevalence of hyperuricemia and its association with other
cardiovascular risk factors in adult Yemeni people of Sana’a city (2019) Clinical Cardiol Cardiovascular
Med 3: 10-14.
11
Bamashmos AM, et al. Clinical Cardiology and Cardiovascular, 2019 PDF: 118, 3:1
Variable
BM
Lean
Normal
Overweight
Obese
WC
Normal
Obese
BP mm/Hg
Normal
High
SUA
Normal
High
FBS; mg/dl
Normal
IFG
Diabetes
T.Ch; mg/dl
Normal
High
TG; mg/dl
Normal
High
HDL; mg/dl
Normal
High
LDL; mg/dl
Normal
High
Men=275
Women=325
Total=600
p-value
27 (9.8%)
125 (45.4%)
85 (30.9)
38 (13.8%)
36 (11%)
148 (45.5%)
85 (26.1%)
56 (17.2%)
63 (10.5%)
273 (44.5%)
170 (28.3%)
94 (15.6%)
235 (85.4%)
40 (14.5%)
211 (64.9%)
114 (35%)
446 (74.3%)
154 (25.6%)
0
225 (81.8%)
50 (18.1%)
231 (71%)
94 (15.5%)
456 (76%)
144 (24%)
0.003
243 (88.3%)
32 (11.6%)
304 (93.5%)
21 (6.4%)
547 (91.1%)
53 (8.8%)
0.185
221 (80.3%)
28 (10.1%)
26 (9.1%)
239 (73.5%)
16 (4.9%)
70 (21.5%)
460 (85.7%)
44 (7.3%)
96 (15.8%)
199 (72.3%)
76 (27.6%)
184 (56.6%)
141 (43.3%)
383 (63.8%)
217 (36.1%)
0
200 (72.7%)
75 (27.2%)
191 (58.7%)
134 (41.2%)
391 (65.1%)
209 (34.8%)
0
251 (91.2%)
24 (8.7%)
262 (80.6%)
63 (19.3%)
513 (85.5%)
87 (12.8%)
0
170 (61.8%)
105 (38.1%)
150 (46.8%)
175 (53.8%)
320 (53.3%)
280 (46.6%)
0.04
0.05
0.05
Note: SUA-Serum Uric Acid, FBS- Fasting Blood Sugar, IFG- Impaired Fasting Glucose, T.Ch- Total Cholesterol, TG- Triglyceride, HDL- High Density Lipoprotein, LDL- Low Density Lipoprotein.
Table 1: Shows the clinical and laboratory characteristics of the study group.
Variable
Age
Systolic blood press
Diastolic blood press
BMI
WC
FBS (mg/dl)
T.Ch (mg/dl )
TG (mg/dl)
HDL (mg/dl )
LDL (mg/dl)
Hyperurecemic subject Mean ± SD
41.2 ± 11.6
118.8 ± 11.2
79.9 ± 7.5
25.4 ± 3.9
88.5 ± 13.4
113.2 ± 64.4
227.0 ± 52.0
243.8 ± 116.7
58.5 ± 19.0
119.8 ± 48.9
Normal subject Mean ± SD
38.4 ± 11.5
114.8 ± 14.2
78.2 ± 8.6
24.7 ± 5.4
84.4 ± 12.7
92.7 ± 38.7
184.1 ± 42.8
131.2 ± 73.1
59.6 ± 19.4
98.6 ± 39.8
P-value
0.034
0.016
0.091
0.207
0.009
0
0
0
0.605
0
Note: Table 2 present comparing the mean of selected study parameters in relation to the uric acid level, it shows the mean of age, SBP, WS, fasting blood glucose, total cholesterol, TG and LDL were
significantly higher within hyperurecemic study population in comparing to those with normal serum uric acid level, there were no significant difference in DBP, BMI and HDL between the two groups.
Table 2: The prevalence of both clinical and laboratory character of person with high and normal serum uric acid.
SUA
Age
SBP
DBP
BMI
WS
FBS
T.CH
TG
HDL
LDL
Personal correlation
0.158**
0.138**
0.092*
0.097*
0.110*
0.159**
0.269**
0.392**
-0.035
0.146**
Sig-(2-tailed)
0
0.001
0.03
0.021
0.017
0
0
0
0.411
0.001
*correlation is significant at the 0.05 level (2-tailed). **correlation is significant at the 0.01 level (2-tailed).
Note: Table 3 shows the simple correlation coefficients between serum uric acid levels and the various cardiovascular risk factors in the population. Uric acid was significantly positively correlated with
age, SBP, FBS ,TG, total cholesterol, LDL (P-value ≤ 0.01) and weak positive correlated with DBP, BMI and WC (P-value ≤ 0.05 ) while it was insignificantly correlated with HDL (P-value 0.411).
Table 3: Shows the correlation between the serum uric acid level and different cardiovascular risk factors.
The mean observations of the present study are the following; firstly
the prevalence of hyperurecemia present in a good proportion in
Yemeni peoples and it was insignificantly high in women than in men.
Secondly significant correlation between serum uric acid the various
cardiovascular risk factors were found.
The prevalence of hyperurecemia in the present study was 8.8%, which
is mainly near to that reported in Saudi Arabia (9.3%), Iran (8%),
Thailand (9-11%), Mexico (11%) and in Turkish (12%) which may be
reflected to similar race and environmental factors. while it’s lower
than that found in Columbia (26.3%).
Citation: Bamashmos AM and Al-Aghbari K. Prevalence of hyperuricemia and its association with other
cardiovascular risk factors in adult Yemeni people of Sana’a city (2019) Clinical Cardiol Cardiovascular
Med 3: 10-14.
12
Bamashmos AM, et al. Clinical Cardiology and Cardiovascular, 2019 PDF: 118, 3:1
Indian (25.8%), Taiwan (30.4%) and USA (21-22%) which may be
attributed to the high economic state of this countries. Hyperurecemia
was insignificantly higher in women (7.9%) than men (6.3%) which
may be explained by high prevalence of obesity in women (BMI and
WC was 17.2%, 35% in women VS 13.8% and 14.1% in in men
respectively. This finding was supported by study done in Saudi Arabia
and but other studies are against this observation. Comparing
hyperurecemic subject with those with normal serum uric acid level,
those with hyperurecemia are older centrally obese, had high systolic
blood pressure, high FBS, total cholesterol, triglyceride, and LDL [3036] (Table 2).
In this study, multiple logistic regression results have further confirmed
the association between metabolic abnormalities and high serum uric
acid, and have conducted further stratified analysis on each metabolic
abnormality-related indicator. Table 3 shows the simple correlation
coefficients between serum uric acid levels and the various
cardiovascular risk factors in the population. Our results have shown
that high serum uric acid was significantly positively correlated with
age, SBP, FBS,TG, total cholesterol, LDL (P-value ≤ 0.01) and weak
positive correlated with DBP, BMI and WC (P-value ≤ 0.05 ) while it
was insignificantly correlated with HDL (P-value 0.411) [35].
Elevation of the serum uric acid level has been known associated with
major cardiovascular risk factors, such as hypertension, insulin
resistance, dyslipidemia and obesity, which are hallmarks of metabolic
syndrome [36-39]. Similar to other studies, in this study, individuals
with hyperuricemia had higher prevalence of major cardiovascular risk
factors, including dyslipidemia, hypertension and overweight. Uric
Acid (UA) is a known endogenous scavenger, which provides a major
part of the antioxidant capacity against oxidative and radical injury.
However, at high levels, UA can shift from an antioxidant to a prooxidant factor (shuttle capacity), depending on the characteristic of the
surrounding microenvironment (e.g., UA levels, acidity, depletion of
other antioxidants, reduced Nitric Oxide (NO), availability) [40,41].
Accordingly, high UA values have been associated with metabolic
syndrome, Cardiovascular Disease (CVD), and renal dysfunction,
involving mechanisms that favor oxidative stress, inflammation, and
endothelial dysfunction. The result of this study showed significant
positive correlation were found between serum uric acid and several
component of the metabolic syndrome such as higher WS, BP, TG and
FBS (p-value ≤ 0.005) but there was insignificant negative correlation
with HDL. Several possible pathophysiological mechanisms have been
evoked to explain these associations including insulin resistance, the
use of diuretics or impaired renal function accompanying hypertension
[42-49].
Indeed the kidney seems to play an important role in the development
of the metabolic syndrome. Insulin-resistant individuals secrete larger
amounts of insulin in order to maintain an adequate glucose
metabolism. The kidney which is not insulin-resistant responds to these
high insulin levels by decreasing uric acid clearance, probably linked to
insulin-induced urinary sodium retention. Insulin resistance may
increase blood pressure directly via enhanced proximal tubular sodium
reabsorption or indirectly by the sympatho-adrenal system [43-45].
Thereby, the kidney has been implicated as the potential link between
muscle insulin resistance and compensatory hyperinsulinemia and the
development of hyperuricemia and eventually hypertension.
Conclusion
Our study demonstrates an alarming high prevalence of hyperurecemia
among Yemeni patients that increases the burden on overstrained
Yemeni health system with uprising CVDs and other hyperurecemia
related health problems e.g. hypertension, dyslipidemia DM.
There is also an urgent need to develop strategies for prevention,
detection, and treatment of hyperurecemia that could contribute to
decreasing the incidence of grave consequences such cardiovascular
disease and chronic renal diseases.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Terkeltaub RA. Clinical practice Gout (2003) N Engl Med
349.
Sachs L, Batra LK and Zimmermann B. Medical implication
of hyperurecemia (2009) Med Healt Rhode Island 92: 353.
Feig DIU, Kang DH and Johnson RJ. Uric acid and
cardiovascular risk (2008) N Engl Med 359: 1811-1821.
Li-ying C, Wen H, Chen Z, Dai H and Ren J. Relationship
between hyperurecemia and metabolic syndrome (2007) J
Zhejiang University Sci 8: 593-598.
Smith E and March L. Global Prevalence of Hyperuricemia: A
Systematic Review of Population-Based Epidemiological
Studies (2015) Am collage rheumatol 9.
Andrew J, Luk M and Simkin P. Epidemiology of
hyperirecemia and gout (2005) Am collage managed care 11:
s435-s442.
Gertler MM, Gam SM and Levine SA. Serum uric acid level in
relation to age and physique in health and coronary heart
diseases (1951) Ann Intern Med 34: 1421-1431.
https://doi.org/10.7326/0003-4819-34-6-1421
Fang J and Alderman MH. Serum uric acid level and
cardiovascular mortality; The NHANES 1 epidemiology
follow up study 1971-1992 (2000) JAMA 283: 2404-2410.
https://doi.org/10.1001/jama.283.18.2404
BurnierM and BrunnerHR. Is hyperurecemia a predictor of
cardiovascular risk? (1999) Curr Opin Nephrol Hypertens 8:
167-172.
Fruehwald SB and PetersA, Kern W and Beyer J. Serum leptin
is associated with serum uric acid concentrations in humans
(1999)
Metabolism
48:
677-680.
https://doi.org/10.1016/s0026-0495(99)90163-4
Perlstein TS, Gumieniak O and Williams GH. Uric acid and
the development of hypertension in normotensive aging study
(2006) Hypertension 48: 1013-1036.
Krishnan E, Kwoh CK, Schumacher HR and Kuller L.
Hyperurecemia and incidence of hypertension among men
without metabolic syndrome (2007) Hypertension 49: 298303. https://doi.org/10.1161/01.hyp.0000254480.64564.b6
Mazzali M, Kanellis J, Han L, Feng L, et al. Hyperurecemia
induce primary arteeriopathy in rats by a blood pressure
independent mechanism (2002) Am J Physiol Renal Physiol
282: F991-F997.
Johnson RJ. Kang DH and Feig D. Is there apathogenetic rule
for uric acid in hypertension and cardiovascular and renal
diseases (2003) Hypertension.
Bosello E and Zamboni M. Visceral obesity and metabolic
syndrome (2000) Obes Rev 1: 47-56.
Leyva F, Wingrove CS and Godsland IF. The glycolytic
pathway to coronary herat diseases; ahypothesis (1998)
Metabolism 47: 6657-662.
Klein BEK, Klein R and Lee KE. Components of metabolic
syndrome and risk of cardiovascular diseases and diabetes in
Beaver Mam (2002) Diabetes Care 25: 1790-1794.
https://doi.org/10.2337/diacare.25.10.1790
Yoo TW, Sung KC, Shin HS, Kim BS, Lee HM, et al.
Relationship between serum uric acid concentration and
insulin resistance and metabolic syndrome (2005) Circ J 9:
928-933. https://doi.org/10.1253/circj.69.928
Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, et al.
Serum uric acid is a determinant of metabolic syndrome in
Citation: Bamashmos AM and Al-Aghbari K. Prevalence of hyperuricemia and its association with other
cardiovascular risk factors in adult Yemeni people of Sana’a city (2019) Clinical Cardiol Cardiovascular
Med 3: 10-14.
13
Bamashmos AM, et al. Clinical Cardiology and Cardiovascular, 2019 PDF: 118, 3:1
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
population-based study (2006) Am J Hypertens 19: 10551062. https://doi.org/10.1016/j.amjhyper.2006.02.014
Allison DB, Downey M, Atkinson RL, et al. Obesity as a
disease: a white paper on evidence and arguments
commissioned by the Council of the Obesity Society (2008)
Obesity
(Silver
Spring)
16:
1161-1177.
https://doi.org/10.1038/oby.2008.231
Hou X, Lu J, Weng J, Ji L, Shan Z, Liu J, Billington JC, Bray
AG, et al. Impact of waist circumference and body mass index
on risk of cardio metabolic disorder and cardiovascular disease
in Chinese adults: a national diabetes and metabolic disorders
survey
(2013)
PLoS
One
8:
e57319.
https://doi.org/10.1371/journal.pone.0057319
European Society of Hypertension-European Society of
Cardiology Guidelines Committee: Guidelines for the
management of arterial hypertension (2003) J Hypertens 21:
1011-1053.
https://doi.org/10.1097/00004872-20030600000001
American Diabetes Association. Standards of Medical Care in
Diabetes-2011 (2011) Diabetes Care 34: S11-S61.
https://dx.doi.org/10.2337%2Fdc11-S011
Expert panel on detection, evaluation and treatment of high
blood cholesterol in adults. Executive summary of the third
report of the National Cholesterol Education Program (NCEP)
(Adult Treatment Panel III) (2001) JAMA 285: 2486-2497.
https://doi.org/10.1001/jama.285.19.2486
Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, et
al. Relationship of uric acid concentration to cardiovascular
risk factors in young men. Role of obesity and central fat
distribution. The verona young men atherosclerosis risk factors
study (1996) Int J Obes Relat Metab Disord 20: 975-980.
Zavaroni I, Mazza S, Fantuzzi M, Dall'Aglio E, Bonora E, et
al. Changes in insulin and lipid metabolism in males with
asymptomatic hyperuricemia (1993) J Intern Med 234: 25-30.
Vuorinen-Markkola H and Yki-Järvinen H. Hyperuricemia and
insulin resistance (1994) J Clin Endocrinol Metab 78: 25-29.
https://doi.org/10.1210/jcem.78.1.8288709
Facchini F, Ida Chen Y-D, Hollenbeck CB and Reaven GM.
Relationship between resistance to insulin-mediated glucose
uptake, urinary uric acid clearance and plasma uric acid
concentration
(1991)
JAMA
266:
3008-3011.
http://dx.doi.org/10.1001/jama.1991.03470210076036
Reaven GM. The kidney: an unwilling accomplice in
syndrome X (1997) Am J Kidney Dis 30: 928-931.
https://doi.org/10.1016/S0272-6386(97)90106-2
Al-arfa AS. Hyperurecemia in Saudia Arabia (2001)
Rhaumatol
Int
20:
61-64.
https://doi.org/10.1007/s002960000076
Smith E and March L. Global Prevalence of Hyperuricemia: A
Systematic Review of Population-Based Epidemiological
Studies (2015) Arthritis Rheumatol 67.
Sari I, Akar S, Pakoz B and Sisman AR. The prevalence of
hyperurecemia in an urban population, Izmer Turkey (2009)
Rheumatol Int 29: 869-874. http://dx.doi.org/10.1007/s00296008-0806-2
Lombo B, Melo AA, Benavides J and Lopez M. Prevalence of
Hyperuricemia and Cardiovascular Risk Factors in a
Population from Colombia (2010) World congress of
cardiology, China, 122.
Billa G, Dargad R and Mehta A. The prevalence of
hyperurecemia in indian subject attending hyperurecemia
screening program -A retrospective study (2018) J the
association of phys ind 66.
Qian Yu, Hsi-che Shen, Yi-chun Hu, Yu-fen Chen and Taohsin Tung. Prevalence and Metabolic Factors of
Hyperuricemia in an Elderly Agricultural and Fishing
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Population in Taiwan (2017) Arch Rheumatol 32: 149-157.
https://doi.org/10.5606/archrheumatol.2017.6075
Masuo K, Kawaguchi H, Mikami H, Ogihara T and Tuck ML.
Serum uric acid and plasma norepinephrine concentrations
predict subsequent weight gain and blood pressure elevation
(2003)
Hypertension
42:
474-480.
https://doi.org/10.1161/01.hyp.0000091371.53502.d3
Sundström J, Sullivan L, D'Agostino RB, Levy D, William B,
et.al. Relations of serum uric acid to longitudinal blood
pressure tracking and hypertension incidence (2005)
Hypertension 45: 28-33.
Li C, Hsieh MC and Chang SJ. Metabolic syndrome, diabetes,
and hyperuricemia (2013) Current opinion in rheumatology
25:210-216. https://doi.org/10.1097/bor.0b013e32835d951e
Puig JG and Martinez MA. Hyperuricemia, gout and the
metabolic syndrome (2008) Current opinion in rheumatology
20:187-191. https://doi.org/10.1097/bor.0b013e3282f4b1ed
Ames BN, Cathcart R, Schwiers E and Hochstein P. Uric acid
provides an antioxidant defense in humans against oxidantand radical-caused aging and cancer: A hypothesis (1981)
Proc
Natl
Acad
Sci
78:
6858-6862.
https://doi.org/10.1073/pnas.78.11.6858
Pingitore A, Lima GP, Mastorci F, Quinones A, Iervasi G,
et.al. Exercise and oxidative stress: Potential effects of
antioxidant dietary strategies in sports (2015) Nutrition
31:916-922. https://doi.org/10.1016/j.nut.2015.02.005
Gliozzi M, Malara N, Muscoli S and Mollace V. The
treatmentof hyperuricemia (2015) Int J Cardiol.
Battelli MG, Polito L and Bolognesi A. Xanthine
oxidoreductase in atherosclerosis pathogenesis: Not only
oxidative stress (2014) Atherosclerosis 237: 562-567.
https://doi.org/10.1016/j.atherosclerosis.2014.10.006
Billiet L, Doaty S and Katz DJ. Review of hyperurecemia as
marker of metabolic syndrome (2014) ISRN Rhaumatology
Pp: 1-7. http://dx.doi.org/10.1155/2014/852954
Reaven GM. The kidney: an unwilling accomplice in
syndrome X (1997) Am J Kidney Dis 30: 928-931.
https://doi.org/10.1016/s0272-6386(97)90106-2
Rathmann W, Funkhouser E, Dyer AR and Roseman JM.
Relations of hyperuricemia with the various components of the
insulin resistance syndrome in young black and white adults:
the CARDIA study. Coronary Artery Risk Development in
Young Adults (1998) Annals Epidemiol 8: 250-261.
https://doi.org/10.1016/s1047-2797(97)00204-4
Agamah ES, Srinivasan SR, Webber LS and Berenson GS.
Serum uric acid and its relations to cardiovascular disease risk
factors in children and young adults from a biracial
community: The Bogalusa Heart Study (1991) J Lab Clin Med
118: 241-249.
Lee J, Sparrow D, Vokonas PS, Landsberg L and Weiss ST:
Uric acid and coronary heart disease risk: evidence for a role
of uric acid in the obesity-insulin resistance syndrome. The
Normative Aging Study (1995) Am J Epidemiol 142: 288-294.
https://doi.org/10.1093/oxfordjournals.aje.a117634
Bruno G, Cavallo-Perin P, Bargero G, Borra M, Calvi V, et.al.
Prevalence and risk factors for micro-and macroalbuminuria in
an Italian population-based cohort of NIDDM subjects (1996)
Diabetes
Care
19:
43-47.
https://doi.org/10.2337/diacare.19.1.43
Citation: Bamashmos AM and Al-Aghbari K. Prevalence of hyperuricemia and its association with other
cardiovascular risk factors in adult Yemeni people of Sana’a city (2019) Clinical Cardiol Cardiovascular
Med 3: 10-14.
14